AstraZeneca Announced At ESMO Sunday, TAGRISSO Plus Savolitinib Extended Median Overall Survival By Nearly Five Months In Patients With EGFRm Lung Cancer
Share
Why It Matters
AstraZeneca's lung cancer medicine helped patients live almost five months longer. This shows the drug works well, which matters when you watch if the company can grow.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.